Dr. Druker is director of the OHSU Knight Cancer Institute, JELD-WEN Chair of Leukemia Research at Oregon Health & Science University, and investigator of the Howard Hughes Medical Institute. Upon graduating from the University of California, San Diego School of Medicine in 1981, Dr. Druker completed his internship and residency in internal medicine at Barnes Hospital, Washington School of Medicine in St. Louis, Missouri. He then trained in oncology at Harvard's Dana-Farber Cancer Institute.

Dr. Druker then returned to the lab to begin his research career studying the regulation of the growth of cancer cells and the practical application to cancer therapies. He developed 4G10, an anti-phosphotyrosine antibody that was an essential reagent to scientists at Novartis in their kinase inhibitor drug discovery program. In collaboration with Novartis, his laboratory performed pre-clinical studies that were instrumental to the development of Gleevec (imatinib), a drug that targets the molecular defect in chronic myeloid leukemia (CML). After completing a series of preclinical studies, Dr. Druker spearheaded the highly successful clinical trials of imatinib for CML. Imatinib is currently FDA approved for CML, gastrointestinal stromal tumors (GIST) and five other cancers.

His role in the development of imatinib and its application in the clinic have resulted in numerous awards for Dr. Druker, including the AACR-Richard and Hinda Rosenthal Award, the Warren Alpert Prize from Harvard Medical School, the American Society of Hematology's Dameshek Prize, the Lance Armstrong Foundation's Pioneer of Survivorship Carpe Diem Award, the American Cancer Society's Medal of Honor, the Kettering Prize from General Motors Cancer Research Foundation, the David A. Karnofsky Award from the American Society of Clinical Oncology, the Robert-Koch Award, and the 2009 Lasker-DeBakey Award for Clinical Medical Research. He was elected to the Institute of Medicine of the National Academies in 2003, the American Association of Physicians in 2006, and the National Academy of Sciences in 2007.

Dr Carolina Pavlovsky, MD

Fundaleu Hospital and Clinical Research Center

Buenos Aires, Argentina

Carolina Pavlovsky works as a hematologist at Fundaleu (Foundation to fight Leukemia) in Buenos Aires and serves as Head of the Research Department since 2010. She received her doctorate from the University of Buenos Aires and completed her training in internal medicine and hematology at the National Academy of Medicine in Buenos Aires.

Her main interests are chronic leukemias: molecular and clinical aspects. Since 2003, she has worked on multiple research protocols for chronic leukemias and is in charge of CML and CLL projects. Since 2005, she has coordinated an Argentine multi-center study on molecular monitoring in patients with CML and since 2011 she coordinates the clinical aspects of a new multi-centric study on mutational analysis of patients with CML and treatment failure. In June 2008, she undertook a training at the Department of Leukemias at the MD Anderson Cancer Center in Houston. In 2014 she obtained a Master's degree in Molecular Oncology from the National Cancer Research Center of Spain (CNIO) and the European School of Oncology (ESO).

Charles A. Schiffer, MD, is Professor of Medicine and Oncology at Wayne State University School of Medicine and the Karmanos Cancer Institute in Detroit, Michigan. He is the director of the Leukemia/Lymphoma Multidisciplinary Program.

Dr. Schiffer earned his BA cum laude at Brandeis University and his M.D. at New York University School of Medicine. He completed his internship, residency, and chief residency in Internal Medicine at Bellevue Hospital under the auspices of New York University School of Medicine and had subsequent training and positions at the Baltimore Cancer Research Institute, National Cancer Institute and the University of Maryland School of Medicine, where he served as Chief of the Division of Hematology. He has also served as Chief of the Division of Hematology/Oncology and Director of Clinical Research at the Karmanos Cancer Institute.

Dr. Schiffer has authored and co-authored more than 300 articles and 80 book chapters on topics concerning the treatment of leukemia in adults, platelet transfusion, and granulocyte transfusion therapy, among others. He has served on the Editorial Boards for Blood, the Journal of Clinical Oncology, International Journal of Hematology, Transfusion Medicine Reviews and Transfusion, and reviews articles for multiple journals. Committee memberships have included Chairman of the Leukemia Committee of the Cancer and Leukemia Group B, Chairman of the Food and Drug Administration Oncologic Drug Advisory Committee, and grant reviews for the NCI and Leukemia/Lymphoma Society of America. Dr. Schiffer has been named among American Health Magazine’s and Castle Connelly’s “Best Doctors in America,” “Best Cancer Specialists in the US.” In 2006, he received the Dr. John J. Kenney Award from the Leukemia/Lymphoma Society of America and the Celgene Award for Career Achievement in Hematology. He has received multiple teaching awards from Wayne State University and was recently inducted into the Academy of Scholars, the highest recognition accorded to academic faculty at the University.

Dr Eduardo Bullorsky

Dr Eduardo Bullorsky graduated at the University of Buenos Aires Medical School in December 1972.

In the period 1973-1976 he completed a Residence on Internal Medicine at the Instituto de Investigaciones Medicas, University of Buenos Aires, with Prof. A. Lanari. In the same Institution he completed a training in Hematology-Oncology in the period 1976-1981 with Dr J. Sanchez Avalos, and in 1981 was selected as a staff physician at the Hospital Britanico (British Hospital) of Buenos Aires, in the Department of Hematology.

In the year 1985, Dr Bullorsky performed a fellowship in the Department of Bone Marrow Transplantation at Hadassah Medical Center, Hebrew University of Jerusalem, Israel, under the direction of Prof. S. Slavin.

In the year 1986, Dr E. Bullorsky performed the first bone marrow transplantation in Argentina, being this the first step for the introduction of this therapeutic in the country.

In the year 1990, Dr Bullorsky was appointed as chief of the Department of Hematology, Blood banking and Bone Marrow Transplantation of the Hospital Britanico (British Hospital) in Buenos Aires, and in 1999 was elected for the period 1999-2001 as president of the Argentinian Society of Hematology.

Dr E. Bullorsky is a teaching professor at the University of Buenos Aires (UBA), and at the Universidad Catolica Argentina (UCA).

He is member of the American Society of Hematology (ASH) and CIBMTR  among other Scientific Societies.

He authored or co-authored more than 200 papers, abstracts and presentations.